We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4887:TSESAWAI GROUP HOLDINGS Co., Ltd. Analysis

Data as of 2026-05-21 - not real-time

¥1,761.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Price action remains trapped below its short‑term moving averages, while the RSI signals a deep oversold condition and the MACD sits firmly in bearish territory. Volume is picking up, yet the market exhibits a neutral trend with volatility well above 50%, suggesting heightened short‑run uncertainty. The stock trades at a price‑to‑earnings multiple that is markedly lower than the industry average, and its price‑to‑book ratio hovers just above one, indicating a valuation gap relative to peers. A solid dividend yield above three percent is being maintained despite a recent patent‑infringement settlement that forced a cut to earnings forecasts, highlighting management’s commitment to cash returns. However, free cash flow is negative and leverage is high, raising questions about the long‑term sustainability of that payout.
The analyst consensus remains bullish with a median target substantially higher than the current price, implying upside potential if the company can navigate the settlement impact and improve cash generation. Forward earnings estimates suggest a steep earnings multiple contraction, reinforcing the undervalued perception. The low beta indicates limited market‑wide price swings, but sector‑specific regulatory headwinds and the company’s debt load temper enthusiasm. Investors should weigh the attractive yield and valuation against the liquidity pressure near support levels and the ongoing regulatory risk. Overall, the stock presents a nuanced case of value appeal tempered by near‑term earnings volatility and balance‑sheet concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near technical support with bearish MACD
  • oversold RSI suggesting possible short‑term bounce
  • settlement expense creating earnings uncertainty

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • valuation gap versus industry and forward PE compression
  • steady dividend yield despite earnings hit
  • analyst target price indicating significant upside

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • potential improvement in cash flow and debt reduction
  • stable demand for generic pharmaceuticals
  • low beta offering defensive characteristics

Key Metrics & Analysis

Financial Health

Revenue Growth2.20%
Profit Margin5.18%
P/E Ratio17.7
ROE6.55%
ROA2.78%
Debt/Equity58.82
P/B Ratio1.1
Op. Cash Flow¥7.4B
Free Cash Flow¥-22596374528
Industry P/E27.1

Technical Analysis

TrendNeutral
RSI25.3
Support¥1,730.50
Resistance¥2,225.00
MA 20¥2,037.48
MA 50¥2,144.97
MA 200¥2,112.00
MACDBearish
VolumeIncreasing
Fear & Greed Index90.29

Valuation

Target Price¥2,677.78
Upside/Downside52.06%
GradeUndervalued
TypeBlend
Dividend Yield3.13%

Risk Assessment

Beta0.07
Volatility50.20%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.